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Summary
ONYX-015 is an E1B-55K-deleted adenovirus that has promising clinical activity as a cancer therapy. However, many
tumor cells fail to support ONYX-015 oncolytic replication. E1B-55K functions include p53 degradation, RNA export, and
host protein shutoff. Here, we show that resistant tumor cell lines fail to provide the RNA export functions of E1B-55K
necessary for ONYX-015 replication; viral 100K mRNA export is necessary for host protein shutoff. However, heat shock
rescues late viral RNA export and renders refractory tumor cells permissive to ONYX-015. These data indicate that heat
shock and late adenoviral RNAs may converge upon a common mechanism for their export. Moreover, these data suggest
that the concomitant induction of a heat shock response could significantly improve ONYX-015 cancer therapy.S I G N I F I C A N C E
ONYX-015 is an E1B-55K mutant adenovirus that undergoes selective lytic replication in tumor cells. In clinical trials, ONYX-015
therapy provoked sustained responses in many cancer patients, but this varied considerably for unknown reasons. Here, we show
that tumor cell differences in providing the late functions of E1B-55K underlie permissivity/resistance to ONYX-015. Moreover, we
demonstrate that the induction of a heat shock response, by incubation at 39.4°C (the temperature of a fever), or with benzoquinoid
ansamycins, phenocopies E1B-55K late functions and selectively sensitizes resistant tumor cells to ONYX-015 oncolytic replication.
This has important clinical applications and suggests that agents that elicit a cellular heat shock response could have a major
impact on the efficacy of ONYX-015 as a cancer therapy.Introduction
Oncolytic viruses that undergo selective lytic replication in tu-
mor cells have the potential to fulfill many of the aspirations
of cancer therapy (Chiocca, 2002; Dobbelstein, 2004; O’Shea,
2005). dl1520/ONYX-015 is the prototype for oncolytic adeno-
viral therapy (Bischoff et al., 1996) and the first such genetic
agent to be tested in humans (Khuri et al., 2000). ONYX-015
lacks the E1B-55K gene product for p53 degradation and
therefore was predicted to selectively replicate in tumor cells
in which the p53 pathway is inactive (Barker and Berk, 1987;
Bischoff et al., 1996). In contrast, in primary cells, the loss of
E1B-55K-mediated p53 degradation was expected to activate
a p53 checkpoint that would limit ONYX-015 replication. Con-
sistent with this, ONYX-015 replication is attenuated in primary
cells but replicates to wild-type virus levels in many tumor cell
lines. In addition to its role in p53 inactivation, E1B-55K has
late functions that include the shutdown of host protein synthe-
sis and the preferential export and translation of late viral
mRNAs, both necessary events for a productive viral infection
(Babiss et al., 1985; Leppard and Shenk, 1989; Pilder et al.,
1986). Recently, it was shown that the loss of E1B-55K-medi-
ated late functions, rather than p53 inactivation, is the major
determinant of ONYX-015’s oncolytic selectivity (O’Shea et
al., 2004).CANCER CELL : JULY 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIER INC.ONYX-015 has undergone extensive clinical testing with
proven safety and evidence of promising clinical activity from
several indications (Khuri et al., 2000; Kirn, 2001; Reid et al.,
2002; Ries and Korn, 2002; Rudin et al., 2003). Initially, ONYX-
015 was evaluated by direct intratumoral injections in head and
neck patients who had failed prior chemotherapy. When
ONYX-015 was combined with conventional chemotherapy,
over 63% of injected tumors showed significant regression
(Khuri et al., 2000). In contrast, normal cells, injected adjacent
to the tumor mass, showed no adverse effects to ONYX-015
therapy. Clinical responses have also been observed in recent
studies, in which ONYX-015 was injected into unresectable
pancreatic carcinomas (Hecht et al., 2003) and peritumoral re-
gions of recurrent malignant gliomas (Chiocca et al., 2004). In
patients suffering from metastatic colorectal cancer, the intra-
vascular delivery of ONYX-015 to the liver provoked tumor re-
gressions, with evidence of prolonged viremia and fever in re-
sponsive patients (Reid et al., 2002). In addition, promising
clinical efficacy was observed when ONYX-015 was adminis-
tered as a mouthwash to patients suffering from premalignant
oral leukoplakia (Rudin et al., 2003). Moreover, ONYX-015 has
recently been “armed” with genes encoding prodrug convert-
ing enzymes (Stubdal et al., 2003) or endostatin (Li et al., 2005),
which would be expected to further enhance ONYX-015’s clin-
ical activity. Taken together, ONYX-015 has a promising clinicalDOI 10.1016/j.ccr.2005.06.009 61
A R T I C L Eprofile for the treatment of disparate tumor types. Nevertheless,
to date ONYX-015 has not completed randomized clinical trials,
so its objective therapeutic value is hard to assess. While many
patients exhibited sustained clinical responses to ONYX-015
treatment, this varied considerably, and some patients experi-
enced no clinical relief of their disease. Therefore, understand-
ing the molecular basis of ONYX-015 tumor cell resistance, or
alternatively, how to sensitize refractory tumor cells to ONYX-
015 treatment, has important therapeutic implications.
In tissue culture, tumor cell lines also vary considerably in
their ability to support ONYX-015 replication (see Table S1 in
the Supplemental Data available with this article online). For
example, ONYX-015 replicates to wild-type virus levels in HCT-
116 colorectal cancer cells (permissive), whereas it is attenu-
ated by almost 100-fold in U2OS osteosarcoma cells (resis-
tant). The aim of this study was to understand the mechanism
underlying tumor cell resistance to ONYX-015, with the ulti-
mate goal of either predicting responsive tumor types and/or
sensitizing refractory cancer cells to ONYX-015 therapy. Here,
we show that, in contrast to permissive tumor cell lines, refrac-
tory tumor cells infected with ONYX-015 fail to shut down cel-
lular protein synthesis in the absence of E1B-55K. We show
that the shutdown of cellular protein synthesis in permissive
tumor cells is a secondary consequence of 100K mRNA ex-
port, an event normally regulated by E1B-55K, and rate limiting
for ONYX-015 replication. The 100K protein acts downstream
of E1B-55K to inhibit the translation of capped cellular mRNAs,
while viral RNAs are preferentially translated due to their pos-
session of a unique 5#UTR (Cuesta et al., 2000b; Hayes et al.,
1990). Moreover, we demonstrate that the induction of a cellu-
lar heat shock response, through physical or pharmacological
means, selectively rescues the export of late viral RNAs, such
as 100K, hexon, and fiber, in resistant tumor cells, rendering
them competent for ONYX-015 replication. These data suggest
that in adenoviral infection and a cellular heat shock response,
RNA export may be similarly regulated. In addition, this study
suggests that the induction of a heat shock response, by fe-
brile temperatures or pharmacological adjuvants, would greatly
enhance the clinical efficacy of ONYX-015 as a cancer therapy.
Results
Tumor cell differences in providing the host protein
shutoff and RNA export functions of E1B-55K correlate
with ONYX-015 permissivity/resistance
Previously, we demonstrated that the propensity of permissive
tumor cells to support ONYX-015 replication correlated with
their unexpected ability to shut down host protein synthesis
and export late viral RNAs in the absence of E1B-55K, a pro-
pensity not shared by primary cells (O’Shea et al., 2004).
Therefore, we hypothesized that the variable replication of
ONYX-015 in tumor cell lines (Table S1) was likely due to tumor
cell differences in providing the late functions of E1B-55K.
Host/viral protein synthesis was measured by analyzing 35S-
methionine-labeled lysates from infected tumor cells. In per-
missive tumor cell lines, such as HCT-116 and C33A, ONYX-
015 infection resulted in the shutdown of host protein synthesis62as efficiently as wild-type virus (WtD), (Figure 1A). In contrast,
the shutoff of host protein synthesis was impaired in ONYX-
015-infected resistant tumor cell lines, such as U2OS and
Ovcar-3.
ONYX-015-infected permissive tumor cells export late viral
RNAs, such as fiber and hexon, five to ten times more effi-
ciently than ONYX-015-infected primary cells (O’Shea et al.,
2004). Therefore, we used an RNA fluorescent in situ hybridiza-
tion assay (FISH) to visualize the localization of the late viral
100K mRNA in resistant and permissive tumor cell lines. In
ONYX-015-infected U2OS cells, 100K mRNA export is delayed
compared to WtD-infected cells (Figure 1B). In contrast, in
HCT-116 cells, 100K mRNA is exported in ONYX-015 infection
analogous to that of WtD (Figure 1C). These data suggest that
differences in providing the late functions of E1B-55K underlie
the variable ability of tumor cell lines to support ONYX-015 rep-
lication.
100K expression is rate limiting for ONYX-015
tumor cell replication
Several previous studies have shown that the presence of cy-
toplasmic fiber and hexon RNAs correlates with tumor cell per-
missivity to ONYX-015 (Goodrum and Ornelles, 1998; Goo-
drum and Ornelles, 1999; Harada and Berk, 1999). However,
this does not appear to explain how host protein shutoff might
also be achieved in the absence of E1B-55K. In Figure 1, we
demonstrate that ONYX-015-infected resistant tumor cells fail
to mediate host protein shutoff and inefficiently export 100K
RNA compared to permissive cell lines. In adenovirus infection,
100K inhibits the translation of many cellular mRNAs but pro-
motes the translation of late viral RNAs (Cuesta et al., 2000b;
Hayes et al., 1990). Consequently, 100K mutant viruses are de-
fective for host protein shutoff and replication (Hayes et al.,
1990; Morin and Boulanger, 1986). Therefore, we hypothesized
that the differences in host protein shutoff in ONYX-015-
infected resistant versus permissive tumor cell lines may, in part,
be explained by disparities in their expression levels of 100K.
Consistent with this hypothesis (and Figures 1B and 1C),
100K expression is defective in ONYX-015-infected U2OS cells
but expressed at WtD levels in ONYX-015-infected HCT-116
cells (Figure 2A). We next investigated whether stable ectopic
expression of 100K would render U2OS cells permissive for
ONYX-015 replication. Ectopic 100K expression resulted in the
enhanced expression of late viral proteins (such as hexon, pen-
ton, and fiber) in ONYX-015-infected U2OS cells (Figure 2B),
consistent with 100K’s role in promoting the translation of late
viral RNAs. Moreover, siRNA-mediated knockdown of 100K re-
duced late viral protein expression in ONYX-015-infected HCT-
116 cells (Figure 2C). In ONYX-015-infected U2OS cells, ec-
topic 100K also resulted in enhanced cytopathic effect (CPE)
and a 10-fold increase in viral yield (Figures 2D and 2E). Never-
theless, ONYX-015 replication was not restored to WtD levels,
possibly because 100K expression was still limiting or, more
likely, due to the still defective export of other critical late viral
RNAs. Notwithstanding, these data demonstrate that 100K ex-
pression is at least one of the critical rate-limiting factors for
ONYX-015 replication and late protein production in resistant
tumor cell lines.CANCER CELL : JULY 2005
A R T I C L EFigure 1. ONYX-015 replicates in tumor cells that
provide the host protein shutoff and RNA export
functions of E1B-55K
A: Host protein shutoff was measured in tumor
cell lines infected with either E1A (a nonrepli-
cating virus and control for infection), ONYX-
015, or wild-type virus (WtD). U2OS and Ovcar-3
minimally support ONYX-015 replication (resis-
tant), while HCT-116 and C33A support ONYX-
015 replication to WtD levels (permissive). In-
fected cells were pulsed with 35S-methionine for
1 hr. Protein lysates were harvested, normalized,
and separated on SDS-PAGE gels; exposed on
a Storm phosphorimager; and analyzed using
Molecular Dynamics software.
B and C: U2OS cells (B) and HCT-116 cells (C)
were infected with either ONYX-015 or WtD and
fixed at 24 hr postinfection (hpi). RNA fluores-
cent in situ hybridization (FISH) was performed
using an antisense digoxigenin-labeled probe
to 100K mRNA and detected with a FITC-
labeled anti-digoxigenin antibody (green); nu-
clei are shown in red. Images were acquired on
a Zeiss Meta confocal laser scanning micro-
scope.Heat shock rescues host protein shutoff and late viral
protein expression in ONYX-015-infected U2OS cells
We conclude that the export and translation of late viral RNAs,
such as 100K (this study), together with hexon and fiber (Goo-
drum and Ornelles, 1998; Goodrum and Ornelles, 1999; Har-
ada and Berk, 1999), in the absence of E1B-55K, determine a
tumor cell’s ability to support ONYX-015 replication. Unfortu-
nately, the mechanics and regulation of mammalian and ade-
noviral RNA export are poorly understood. In contrast, more is
known about the control of mRNA translation, including that of
late adenoviral RNAs. In Figure 2E, we show that ectopic 100K
expression, which promotes late viral mRNA translation (Cuesta
et al., 2000b), rescues ONYX-015 replication by up to 10-fold
in the resistant U2OS tumor cell line. Therefore, we reasoned
that selectively invoking 100K-like functions in resistant tumorCANCER CELL : JULY 2005cells might significantly broaden the clinical application and ac-
tivity of ONYX-015 as a cancer therapy.
In many ways, the cellular response to heat shock resembles
the late stages of adenovirus infection. During a heat shock
response, the translation of cellular mRNAs is inhibited, to pre-
vent the further accumulation of misfolded proteins. However,
heat shock mRNAs are preferentially translated via a ribosome
shunting mechanism, whereupon they promote cell survival
through their functions as molecular chaperones (Rhoads and
Lamphear, 1995). The 5#UTR of mammalian Hsp70 and late
adenoviral mRNAs share significant structural homology, which
facilitates their selective translation through a common mecha-
nism in a cellular heat shock response or viral infection (Yueh
and Schneider, 2000). dl1520/ONYX-015 has previously been
described as a “cold-sensitive” virus and replicates poorly at
low temperatures (Harada and Berk, 1999; Ho et al., 1982;63
A R T I C L EFigure 2. 100K expression is regulated by E1B-55K and rate limiting for ONYX-015 replication in tumor cells
A: 100K expression was analyzed by Western blotting of lysates from U2OS or HCT-116 tumor cells that had been infected with either E1A, ONYX-015,
or WtD.
B: Control and myc-100K-expressing U2OS cells were infected with either ONYX-015 or WtD. Protein lysates were examined by Western blotting for the
expression of Ad5 proteins (hexon, penton, and fiber), p53, and myc-100K.
C: HCT-116 cells were transfected with either 100K siRNA or nonsilencing control siRNA and infected with ONYX-015. Protein lysates were examined for 100K
and Ad5 late protein expression.
D and E: Stable U2OS cell clones for either myc-100K or control vector were infected with either E1A, ONYX-015, or WtD. D: Cytopathic effect (CPE) was
visualized at 72 hpi. E: ONYX-015 and WtD viral yield at 48 hpi was measured by quantifying total plaque-forming units (pfu) in 293E4s.Leppard and Shenk, 1989). Therefore, we wondered if the
“cold sensitivity” might instead be a “heat dependency,” and if
heat shock would enhance late viral protein expression in
ONYX-015-infected U2OS cells.
We examined late protein expression in ONYX-015-infected
U2OS cells at various temperatures. Temperatures of 39.4°C–
40°C for 4–18 hr postinfection (hpi) were sufficient to enhance
the expression of late viral proteins in ONYX-015-infected
U2OS cells, although prolonged incubation at 44°C was too
severe and inhibited late viral protein synthesis even in WtD-
infected cells (Figure S1 and data not shown). Incubation at
39.4°C significantly rescues the expression of the majority of
late viral proteins in ONYX-015-infected U2OS cells, including
hexon, penton, fiber, V, VI, and VII (Figure 3A). We also ob-
served a protein of approximately 33 kDa that is absent in
ONYX-015-infected lysates compared to WtD, and which is not
rescued by heat shock. The molecular weight of this protein
would be consistent with that of the late viral L4-33K protein,
which functions in virion assembly and the early to late switch
in viral protein expression (Farley et al., 2004; Fessler and
Young, 1999). However, 33K is not present in the mature virion,
and antisera raised against mature viral particles would not be64expected to detect it. Nevertheless, given the functions of 33K,
we are currently investigating the identity of this cryptic 33 kDa
protein band.
Since 39.4°C is within the range of temperatures experi-
enced by patients exposed to high doses of ONYX-015 (Reid
et al., 2001), we chose to study the effect of this temperature
on ONYX-015 replication further. Incubation at 39.4°C results
in a bona fide cellular heat shock response as evidenced by
the induction of heat shock mRNAs such as Hsp70, Crystallin
αB, Hsp27, and Hsp90 (Figure 3B). In Figure 3C, we show that
incubation at 39.4°C also rescued 100K expression in ONYX-
015-infected U2OS cells and, consistent with this, host protein
shutoff (Figure 3D).
Heat shock rescues the export of late viral RNAs
in ONYX-015-infected U2OS cells
We next investigated the mechanism whereby heat shock res-
cues late viral protein synthesis and host protein shutoff in
ONYX-015-infected U2OS cells. The inhibition of cap-depen-
dent translation in mammalian cells exposed to chronic heat
shock (44°C) is thought to be mediated through a reduction in
soluble eIF-4G, and consequently phospho-eIF-4E, bound toCANCER CELL : JULY 2005
A R T I C L EFigure 3. Heat shock rescues host protein shutoff and late viral protein production in ONYX-015-infected refractory tumor cells
A: U20S cells were infected with either ONYX-015 or WtD. Protein lysates were examined by Western blotting for the expression of late viral proteins.
Molecular weight (MW) in kD and the identity of late viral proteins (based on known specificity of antisera and MW) are marked.
B: U2OS cells were incubated at either 37°C or 39.4°C for 24 hr. RNA was extracted and analyzed for the expression of Hsp genes using an Affymetrix
HGU133A GeneChip. Intensity values were calculated using Affymetrix Microarray Suite software. The average values of three independent experiments
are plotted.
C: U2OS cells were infected with either E1A, ONYX-015, or WtD and incubated at 39.4°C. 100K expression was examined by Western blotting.
D: U2OS cells were infected with either ONYX-015 or WtD and incubated at 37°C or 39.4°C. Host protein shutoff was analyzed at 48 hpi.methyl7 GTP (Cuesta et al., 2000a). However, in Figure 4A, we
show that incubation of U2OS cells at 39.4°C does not reduce
either the total levels of phospho-eIF-4E or the fraction of eIF-
4E capable of binding to the cap analog methyl7 GTP sepha-
rose. Indeed, this is consistent with the original report of heat
shock effects on translation, which demonstrated that the eIF-
4G-heat/stress granules do not form at lower temperatures
(Cuesta et al., 2000a), such as, in our case, 39.4°C. Therefore,
effects on eIF-4E at 39.4°C do not appear to account for the
shutdown in cellular protein synthesis observed in ONYX-015-
infected U2OS cells in Figure 3D.
We next investigated whether heat shock increased the tran-
scription of late viral mRNAs such as 100K and fiber in ONYX-
015-infected U2OS cells. However, the ratio of 100K or fiber
mRNA levels in ONYX-015- versus WtD-infected U2OS cells
did not increase at 39.4°C compared to 37°C (Figure 4B). In
yeast, heat shock has been shown to induce the preferential
nuclear export of Hsp mRNAs, while global RNA export is con-
comitantly inhibited (Saavedra et al., 1996; Saavedra et al.,
1997). Therefore, we examined whether the incubation of
ONYX-015-infected U2OS cells at 39.4°C rescues the export
of late viral RNAs, which, as we have demonstrated, appears
to be the major limitation to ONYX-015 replication in these
cells. Figure 4C demonstrates that incubation at 39.4°C wasCANCER CELL : JULY 2005sufficient to rescue the export of 100K mRNA (and by inference
host protein shutoff) in ONYX-015-infected U2OS cells. Heat
shock also rescued, albeit to a lesser extent, the export of
other late viral RNAs, such as fiber and hexon (Figure 4D and
Supplemental Data, respectively). From this we conclude that
incubation of ONYX-015-infected U20S cells at 39.4°C pheno-
copies the functions of E1B-55K in the export of the late viral
RNAs, 100K, hexon, and fiber, together with host protein
shutoff.
Heat shock rescues ONYX-015 replication
in nonpermissive tumor cells
We next determined whether heat shock-induced late viral
RNA export was sufficient to rescue ONYX-015 replication in
resistant tumor cells. Incubation of U2OS cells at 39.4°C re-
sulted in CPE (Figure 5A) and a 30-fold increase in ONYX-015
viral yield (Figure 5B). In contrast, WtD yield increased by at
most 2-fold at the elevated temperature, as has been noted
before (Haviv et al., 2001).
We next investigated whether a heat shock response could
rescue ONYX-015 replication in a panel of resistant tumor cell
lines. Incubation of ONYX-015-infected MDA-MB-231, MDA-
MB-453, SK-BR-3, HCC38, HCC3153, and MDA-MB-415 tu-
mor cell lines at 39.4°C rescued the expression of late viral65
A R T I C L EFigure 4. Heat shock rescues late viral RNA export in ONYX-015-infected U2OS cells
A: U2OS cells were infected with a E1A virus and incubated at either 37°C or 39.4°C. Lysates were examined by Western blotting (upper panel) for
phospho-ser-209-eIF-4E. In addition, the ability of both total and phospho-ser-209-eIF-4E to bind to capped mRNAs was examined by precipitation with the
cap analog methyl7 GTP sepharose (lower panel).
B: RNA was extracted from U2OS cells infected with either ONYX-015 or WtD and incubated at either 37°C or 39.4°C. Fiber and 100K mRNA levels were
quantified by real-time Q-PCR and normalized relative to 18S.
C and D: U2OS cells were infected with ONYX-015 and incubated at either 37°C or 39.4°C. Cells were fixed at 24 hpi and analyzed for 100K (C) and fiber
(D) RNA export by FISH.proteins, as shown in Figure 5C. Moreover, incubation at
39.4°C also resulted in, on average, an 8-fold increase in
ONYX-015 replication (Table 1). In contrast, the incubation of
ONYX-015-infected permissive tumor cell lines, such as C33A,
at 39.4°C resulted in at most a 2-fold increase in replication
(Figure S3) and had minimal effects on late protein expression,
ostensibly because E1B-55K late functions are already com-
plemented.
Benzoquinoid ansamycins rescue ONYX-015 production
in resistant tumor cells
The effects of elevated temperatures on ONYX-015 replication
could be due to the destabilization of temperature-sensitive
proteins and/or the induction of a cellular heat shock response.
Therefore, we investigated whether pharmacological inducers
of a heat shock response could also rescue ONYX-015 replica-
tion in resistant tumor cells. One such class of compounds is
the benzoquinoid ansamycins, which include herbimycin A
(Hegde et al., 1995), radicicol, geldanamycin, and 17-AAG
(Neckers, 2002). These compounds block Hsp90 chaperone66function, thereby provoking a secondary misfolded protein/
heat shock response, which includes the induction of Hsp70.
Herbimycin A resulted in a strong induction of Hsp70 in E1A
(a nonreplicating virus control for infection)-infected U2OS
cells, consistent with a bona fide heat shock response (Figure
6A). Herbimycin A, like elevated temperature, also rescued
100K protein expression (Figure 6B) and host protein shutoff in
ONYX-015-infected U2OS cells (Figure 6C). In addition, herbi-
mycin A increased ONYX-015 viral yield, without overtly affect-
ing that of WtD, in infected U2OS cells (Figure 6D). We also
conducted a dose-response experiment with herbimycin A/gel-
danamycin to determine if there was an optimal concentration
that would maximally rescue ONYX-015 replication in U2OS
cells (Figure 6E). We found that a concentration of 200–400 ng/
ml geldanamycin increased ONYX-015 viral yield up to 130-
fold, close to a complete rescue to WtD levels.
Similar to incubation at 39.4°C, treatment with benzoquinoid
ansamycins enhances the yield of ONYX-015 in a panel of re-
sistant tumor cell lines (Table 1). Geldanamycin or 17-AAG re-
sulted in a 10-fold, or greater, increase in ONYX-015 replicationCANCER CELL : JULY 2005
A R T I C L EFigure 5. Heat shock rescues ONYX-015 replication in resistant tumor cells
A: CPE at 64 hpi in U2OS cells infected with either E1A, ONYX-015, or WtD and incubated at either 37°C or 39.4°C.
B: U2OS cells were infected with either ONYX-015 or WtD and incubated at either 37°C or 39.4°C. Virus replication was measured at 48 hpi.
C: Resistant tumor cells were infected with ONYX-015 and incubated at either 37°C or 39.4°C. Protein lysates were harvested at 24 hpi and examined by
Western blotting for the expression of E1A and late viral proteins.in eight out of ten resistant tumor cell lines tested. Taken to-
gether, these data demonstrate that drugs that elicit a heat
shock response can significantly rescue ONYX-015 replication
in many refractory tumor cell lines.
Induction of a cellular heat shock response fails to rescue
ONYX-015 replication in primary human cells
To have a potential clinical application, the induction of a cellu-
lar heat shock would have to maintain, or indeed improve, the
therapeutic index of ONYX-015 for tumor versus normal cells.
Previously, we found that ONYX-053, a novel adenovirus mu-
tant that is defective for E1B-55K-mediated p53 degradation
but retains E1B-55K late functions (Shen et al., 2001), repli-
cated to almost wild-type virus levels in primary cells (O’Shea
et al., 2004). Thus, our attempts at genetically engineering an
E1B-55K mutant virus with enhanced replication in resistant
tumor cell lines also ablated oncolytic selectivity. Therefore, we
would have expected the induction of a cellular heat shock
response to have a similar effect, and to rescue ONYX-015 rep-
lication in primary cells, obviating any potential clinical utility of
a heat shock/ONYX-015 combination cancer therapy.
Notwithstanding, we examined the effect of elevated tem-
perature and herbimycin A on ONYX-015 replication in primary
quiescent small airway epithelial cells (SAECs). We used quies-CANCER CELL : JULY 2005cent primary cells, to try to reflect the physiological state of the
majority of normal epithelial cells within the body. In contrast
to resistant tumor cells, heat shock did not rescue 100K ex-
pression in ONYX-015-infected primary SAECs (Figure 7A). In-
deed, in infected SAECs, ONYX-015 replication was further at-
tenuated by incubation at 39.4°C, or by treatment with
herbimycin A, as shown in Figure 7B. Surprisingly, WtD replica-
tion was also attenuated by up to 50-fold under these condi-
tions. Moreover, these conclusions hold true for a panel of pri-
mary cells. Incubation at 39.4°C or treatment with herbimycin
A/geldanamycin, for the most part, decreased ONYX-015 repli-
cation in primary keratinocytes, astrocytes, mammary epithelial
cells, and bronchial epithelial cells (Figure 7C and Table S2).
Treatment with 17-AAG resulted in up to 2.1-fold increases in
ONYX-015 viral yield in primary cells, but in comparison to tu-
mor cells, these effects are minimal. In addition, heat shock
appears to decrease both WtD and ONYX-015 viral yield irre-
spective of whether normal cells were proliferating or rendered
quiescent prior to infection.
We examined whether a heat shock response resulted in pre-
mature apoptosis, cell cycle arrest, or defective p53 degrada-
tion in adenovirus-infected primary cells. Heat shock had no
appreciable effect on apoptosis or cell cycle entry, as evi-
denced by PARP/caspase 3 cleavage or cyclin A induction (an67
A R T I C L ETable 1. ONYX-015 replication in resistant tumor cells incubated at either 37°C
or 39.4°C, or in the presence of benzoquinoid ansamycins
Viral yield Fold change relative
Cell line Treatment (pfu × 106) to 37°C
U2OS 37°C 1.05 1.0
(48 hpi) 39.4°C 13.52 12.9
(72 hpi) 37°C 1.86 1.0
herbimycin A 29.67 15.9
(72 hpi) 37°C 2.49 1.0
geldanamycin 323.11 129.6
radicicol 83.59 33.5
MDA-MB-231 37°C 8.67 1.0
(72 hpi) geldanamycin 122.75 14.2
17-AAG 288.38 33.2
39.4°C 162.86 18.8
MDA-MB-453 37°C 68.08 1.0
(48 hpi) geldanamycin 123.24 1.8
17-AAG 361.40 5.3
39.4°C 315.56 4.6
Ovcar-3 37°C 9.59 1.0
(72 hpi) geldanamycin 98.42 10.3
herbimycin A 45.85 4.8
39.4°C 29.52 3.1
SK-BR-3 37°C 18.21 1.0
(72 hpi) geldanamycin 190.72 10.5
17-AAG 44.08 2.4
39.4°C 99.36 5.5
MDA-MB-415 37°C 3.49 1.0
(48 hpi) geldanamycin 34.68 9.9
39.4°C 83.74 24.0
MDA-MB-436 37°C 8.97 1.0
(48 hpi) geldanamycin 89.38 10.0
39.4°C 33.25 3.7
LNCaP 37°C BLD (<106) 1.0
(72 hpi) geldanamycin 6.38 >6.3
herbimycin A 6.00 >6.0
39.4°C BLD (<106)
HCC38 37°C 7.80 1.0
(48 hpi) geldanamycin 14.20 1.8
17-AAG 4.16 0.5
39.4°C 21.51 2.8
HCC3153 37°C 13.53 1.0
(72 hpi) geldanamycin 25.83 1.9
17-AAG 17.18 1.3
39.4°C 24.22 1.8
Resistant tumor cell lines were infected with ONYX-015 and incubated at either
37°C or 39.4°C, or in the presence of benzoquinoid ansamycins. Radicicol was
used at 5 M; 17-AAG was used at 100 ng/ml; herbimycin A was used at 500
ng/ml, except for LNCaP, which received 2500 ng/ml; and geldanamycin was
used at 100 ng/ml, except for U2OS, Ovcar-3, and LNCaP, which received 400
ng/ml, and MDA-MB-231 and -453, which received 500 ng/ml. Viral yield was
measured at 48 and 72 hpi by quantifying total plaque-forming units (pfu) in
293E4s. Data for either 48 or 72 hpi are shown and reflect the time point at which
viral yield (untreated) peaked in the respective tumor cell lines. BLD, below limit
of detection; hpi, hours postinfection.E2F target), respectively (Figure 7D). WtD degraded p53 at
both 37°C and 39.4°C, implying that the effects of heat shock
in decreasing wild-type viral replication were not related to ef-
fects on p53. This suggests that the disparity between normal
and tumor cells with respect to the effect of heat shock on
virus production may be unrelated to the disruption of the RB/
p53 checkpoints and reflect a novel difference. Taken together,
these data indicate that the combined use of ONYX-015 with
agents that elicit a heat shock response could significantly im-
prove and broaden ONYX-015’s therapeutic utility.68Discussion
Oncolytic viruses are a novel and promising approach to can-
cer therapy. ONYX-015 was one of the first oncolytic adenovi-
ral agents to be tested in the clinic, where it was found to be
safe with evidence of promising activity in Phase I and II clinical
trials (Khuri et al., 2000; Kirn, 2001; Reid et al., 2002; Ries and
Korn, 2002; Rudin et al., 2003). Nevertheless, ONYX-015 has
yet to be evaluated in Phase III clinical trials and, therefore,
remains an unproven therapy. Two of the major factors that
stalled the further clinical evaluation of ONYX-015 were the
controversy surrounding its p53 tumor selectivity, together with
its variable tumor cell replication. Thus, while many cancer pa-
tients exhibited sustained complete/partial responses to ONYX-
015 therapy, which would potentially recommend its clinical ap-
proval, many were resistant to ONYX-015, for reasons apparently
unrelated to the p53 status of their tumors (Khuri et al., 2000).
Recently, the role of p53 in determining ONYX-015 tumor se-
lectivity has been resolved. In ONYX-015-infected cells, p53 is
induced, but not activated, and therefore plays a minimal role
in limiting viral replication, at least in vitro (Hobom and Dob-
belstein, 2004; O’Shea et al., 2004). Instead, the complementa-
tion of E1B-55K late functions in tumor cells appears to be the
major determinant of ONYX-015 oncolytic selectivity (Goodrum
and Ornelles, 1998; Rothmann et al., 1998; Harada and Berk,
1999; Turnell et al., 1999; O’Shea et al., 2004).
The aim of this study was to determine the molecular mecha-
nism underlying the variable replication of ONYX-015 in tumor
cells with the ultimate goal of sensitizing refractory tumor cells
to ONYX-015 therapy. Here, we demonstrate that a tumor cell’s
ability to provide the host protein shutoff and late viral RNA
export functions of E1B-55K determines ONYX-015 permissiv-
ity/resistance. Nevertheless, it was not clear how altered RNA
export in permissive tumor cells could provoke host protein
shutoff, or if indeed this was a distinct property of permissive
tumor cell lines. Here, we demonstrate that E1B-55K regulates
the export of 100K RNA, which, upon translation in the cyto-
plasm, functions downstream of E1B-55K to mediate the shut-
down of host protein synthesis and enhance the expression of
late viral proteins. In addition, 100K also plays an important
role in hexon trimerization and viral assembly (Cepko and
Sharp, 1982; Morin and Boulanger, 1986). We show that 100K
expression is limiting in ONYX-015-infected resistant tumor
cells, and necessary in ONYX-015-infected permissive tumor
cells. These data resolve the dual functions of E1B-55K in host
protein shutoff and late viral RNA export to a single function:
late viral RNA export of capsid RNAs such as fiber and hexon,
and 100K RNA for host protein shutoff and viral morphogene-
sis. Similarly, the ability of permissive tumor cells to support
ONYX-015 replication also resolves to a single property: the
export of late viral RNAs in the absence of E1B-55K.
Our next objective was to try to extend ONYX-015 replica-
tion to refractory tumor cells. However, the molecular mecha-
nisms underlying both adenoviral and mammalian RNA export
are poorly understood, and not obviously tractable to manipu-
lation. Therefore, given that ectopic expression of 100K in
U2OS cells increased ONYX-015 replication by up to 10-fold,
we initially chose to focus on strategies that might be used
therapeutically to mimic 100K-mediated translation of late viral
RNAs. However, neither rapamycin treatment, which inhibits
mTOR, nor SB203580 together with U0126 treatment, whichCANCER CELL : JULY 2005
A R T I C L EFigure 6. Herbimycin A and geldanamycin rescue ONYX-015 in resistant U2OS cells
A: U2OS cells were mock infected with E1A virus and treated with herbimycin A (500 ng/ml). Hsp70 expression was analyzed by Western blotting.
B: U2OS cells were infected with either E1A, ONYX-015, or WtD and treated with herbimycin A (500 ng/ml). Protein lysates were analyzed for 100K
expression by Western blotting.
C: Host protein shutoff was examined at 48 hpi in U2OS cells infected with either E1A, ONYX-015, or WtD and incubated in the presence/absence of
herbimycin A (500 ng/ml).
D: ONYX-015 or WtD viral yield was measured in U2OS cells incubated in the presence/absence of herbimycin A (500 ng/ml).
E: A dose-response curve with herbimycin A or geldanamycin was performed in ONYX-015-infected U2OS cells. Viral yield was measured at 48 hpi.inhibits mnk-1 phosphorylation of eIF-4E (Wang et al., 1998),
nor expression of the poliovirus 2apro, which cleaves eIF-4G
(Castrillo and Carrasco, 1987), rescued 100K functions and late
viral protein production in ONYX-015-infected U2OS cells (data
not shown). Indeed, this is perhaps not surprising in light of
recent elegant studies, which revealed that 100K possesses a
selective binding element for the tripartite leader of late viral
RNAs, and simultaneously binds to eIF-4G (consequently dis-
placing mnk), to drive 40S ribosome recruitment and the trans-
lation of viral RNAs (Cuesta et al., 2004). Nevertheless, our in-
hibitor experiments imply that any nominal strategy that
decreases the translation of cellular mRNAs does not neces-
sarily mimic the specific effects of a heat shock response on
ONYX-015 replication.
E1B-defective adenoviruses have been described as “cold-
sensitive viruses” (Ho et al., 1982). Recent studies, which made
use of temperature-sensitive p53 mutants (stable at 32°C and
unstable at 39°C) to examine the role of p53 on ONYX-015
replication, also reported a confounding effect of temperature
on ONYX-015 replication, irrespective of whether p53 was pre-CANCER CELL : JULY 2005sent or not. Indeed, a severe defect in late viral protein synthe-
sis was observed at 32°C in the H1299 tumor cell line (Harada
and Berk, 1999). However, there was only a modest, at most
2-fold, decrease in cytoplasmic fiber and hexon mRNA, and so
effects of temperature on viral protein translation were conjec-
tured as the likely cause. These studies, together with the
knowledge that heat shock and late viral RNAs have structur-
ally similar 5#UTRs (Yueh and Schneider, 2000), prompted us
to determine if heat shock could rescue ONYX-015 replication
in resistant tumor cells. Incubation of refractory tumor cells at
39.4°C rescued late viral protein expression and host protein
shutoff. The relatively mild heat shock temperature of 39.4°C
did not affect phospho-eIF-4E binding to methyl7 GTP in
ONYX-015-infected U2OS cells. Instead, heat shock induces
resistant tumor cells to export late viral RNAs, the primary im-
pediment to ONYX-015 replication in these cells. Thus, heat
shock-mediated host protein shutoff in ONYX-015-infected
nonpermissive tumor cells is most likely a secondary result of
100K RNA export and expression.
We find that late viral messages depend on E1B-55K for their69
A R T I C L EFigure 7. Induction of a cellular heat shock re-
sponse fails to rescue ONYX-015 replication in
primary human cells
A: Primary quiescent small airway epithelial cells
(SAECs) were infected with either E1A, ONYX-
015, or WtD and incubated at either 37°C or
39.4°C. 100K expression was examined by West-
ern blotting.
B: Viral production was measured in SAECs that
had been infected with either ONYX-015 or WtD
and incubated at either 37°C or 39.4°C, or in the
presence of 500 ng/ml herbimycin A.
C: The ratio/fold change of ONYX-015 viral yield
at 72 hpi in infected quiescent (Q) or proliferat-
ing (P) primary cells incubated at either 39.4°C,
or in the presence of either herbimycin A
(SAECs), geldanamycin (500 ng/ml), or 17-AAG
(100 ng/ml), is shown relative to cells incubated
at 37°C. Actual titers obtained in these experi-
ments are included in Table S2. Herb A, herbi-
mycin A; Geld A, geldanamycin; HMECs, hu-
man mammary epithelial cells; BLD, below limit
of detection; ND, not done.
D: SAECs were infected with either E1A, ONYX-
015, or WtD and incubated at either 37°C or
39.4°C. Protein lysates were harvested and ex-
amined by Western blotting with the indicated
antibodies.export to different degrees, with hexon > fiber > 100K, and that
this is also reflected in the extent to which a heat shock re-
sponse rescues their export (Figures 4C and 4D and Figure
S2). This may reflect the temporal expression of these mes-
sages (Farley et al., 2004), their distance from the late viral pro-
moter (Flint and Gonzalez, 2003), or molecular motifs within
these RNAs that influence their mode of export. In addition,
the extent to which late viral proteins depend on E1B-55K for
their expression is not absolute but instead particularly ex-
acerbated early in infection. One explanation for this is that late
viral RNA transcripts accumulate over time and so can more
effectively compete with cellular RNAs for nuclear export and/
or translation, despite the absence of E1B-55K/100K. In addi-
tion, 100K and L4-33K have been proposed to contribute to a
“feed-forward” activation mechanism in mediating the early/
late switch (Farley et al., 2004), that may also account for the70kinetics of late protein expression observed in ONYX-015-
infected cells. Nevertheless, the ability of heat shock to rescue
late viral RNA export and consequently ONYX-015 replication
indicates that it is a critical rate-limiting factor in resistant tu-
mor cells.
We also demonstrate that pharmacological inducers of a
heat shock response, such as the benzoquinoid ansamycins,
rescue late protein expression, host shutoff, and viral replica-
tion in ONYX-015-infected resistant tumor cells. These agents
inhibit Hsp90, which triggers a misfolded protein response and
induction of Hsp70, akin to elevated temperature (Hegde et al.,
1995). Therefore, the effects of heat shock on late viral RNA
export are unlikely to be mediated through Hsp90, given that
herbimycin A inhibits this family of Hsps. Recently, the induc-
tion of Hsp70 and Hsp40 by the avian adenovirus protein
GAM-1 was shown to be essential for virus replication, andCANCER CELL : JULY 2005
A R T I C L EGAM-1 mutants were partially rescued by heat shock (Glotzer
et al., 2000). However, Hsp70 is unlikely to mediate the effects
of heat shock in ONYX-015 replication, as it is potently induced
by E1A (the GAM-1 functional equivalent) in both wild-type
(Nevins, 1982; Wu et al., 1986) and ONYX-015-infected cells
(data not shown). Incubation of resistant tumor cells at 39.4°C
for 10 hr early in infection is sufficient to rescue the effects
of E1B-55K in late viral replication. This is consistent with the
induction of an ordered sequelae of events during a heat shock
response, such as activation of the heat shock transcription
factor HSF-1 by both temperature (Cotto and Morimoto, 1999)
and geldanamycin (Zou et al., 1998). However, overexpression
of a constitutively active HSF-1 (Hegde et al., 1995) fails to
rescue late viral protein expression in ONYX-015-infected
U2OS cells (data not shown). The preferential export of heat
shock RNAs has previously been observed upon heat shock of
yeast, but the molecular mechanism is controversial, and the
mammalian factors remain to be elucidated (Jensen et al.,
2001; Saavedra et al., 1996; Santoro, 2000; Vainberg et al.,
2000). Therefore, a novel component of the heat shock path-
way appears to mediate these effects, which we are currently
investigating.
Our data suggest that heat shock and late viral RNAs may
impinge on a common molecular mechanism for their nuclear
export. Consistent with this, Hsp70 mRNA continues to be ex-
ported to the cytoplasm late in viral replication, when the trans-
port of most cellular RNAs is inhibited (Moore et al., 1987).
From these data, we infer that late viral and Hsp RNAs may
share a molecular resemblance that dictates their mode of ex-
port. The 5#UTR of late adenoviral RNAs has structural homol-
ogy to the 5#UTR of Hsp70 and 18S rRNA (Yueh and Schnei-
der, 2000), which underlies their common property to be
translated by ribosome shunting. In addition to its role in trans-
lation, the 5#UTR of late viral mRNAs has also been shown to
play a role in export (Huang and Flint, 1998). Taken together,
these data suggest that heat shock and late viral RNAs may
share a common strategy for both translation and nuclear ex-
port that is specified by their 5#UTRs.
The upregulation of Hsps in tumor cells is well documented
(Jolly and Morimoto, 2000). Therefore, it is intriguing to specu-
late that permissive tumor cells may constitutively deregulate
cellular players in the RNA export pathway that play a role in
heat shock/stress responses. Interestingly, the localization of
YB-1, which plays a role in the transcription of multidrug resis-
tance genes, is affected by both E1B-55K and heat shock
(Holm et al., 2002; Holm et al., 2004; Raffetseder et al., 2003)
and has recently been shown to have RNA binding functions
that regulate mRNA translation (Bader et al., 2003).
These data have important and immediate clinical implica-
tions for ONYX-015 cancer therapy. Incubation at 39.4°C, or
treatment with geldanamycin/17-AAG, enhances the replica-
tion of ONYX-015 in a panel of resistant tumor cell lines. In-
deed, geldanamycin/17-AAG resulted in a 10-fold, or greater,
increase in ONYX-015 viral yield in eight out of ten resistant
tumor cell lines tested. Nevertheless, inevitably, as with any
therapy, in some tumor cell lines, such as HCC38 and
HCC3153, geldanamycin resulted in only a 2- to 3-fold in-
crease in ONYX-015 replication. Reasons for this may include
a common polymorphism in DT-diapharose (Kelland et al.,
1999), or differences in the expression of the latter together
with CYP3A4 (Egorin et al., 1998), quinine metabolizing en-CANCER CELL : JULY 2005zymes that are thought to affect the efficacy of geldanamycin/
17-AAG. Also, while we performed dose-response experiments
in U2OS cells to determine an optimal concentration of gelda-
namycin that rescued ONYX-015 replication by up to 130-fold
(almost to the level of wild-type virus) (Figure 6E), due to practi-
cal considerations, this was not possible for all tumor cell lines
tested. The ability of heat shock-induced late viral RNA export
to fully rescue ONYX-015 to wild-type virus levels may also be
compromised by “off-target” effects that negatively impact viral
replication. Nevertheless, our data indicate that the induction
of a cellular heat shock could extend ONYX-015 oncolytic ther-
apy to many formerly refractory tumor cells.
The effects of heat shock in enhancing ONYX-015 replication
are restricted to tumor cells and, surprisingly, impair both wild-
type and ONYX-015 viral replication in primary SAECs. This
may reflect a differential heat shock response in tumor versus
normal cells. Indeed, tumor-specific differences in Hsp regula-
tion (Kamal et al., 2003) have been proposed to underlie the
cancer selectivity of drugs, such as geldanamycin/17-AAG,
which are currently undergoing clinical evaluation. Notwith-
standing, our data indicate that heat shock appreciably en-
hances the therapeutic index of ONYX-015 for tumor versus
normal cells. This is in sharp contrast to results obtained with
ONYX-053 (Shen et al., 2001), a mutant virus that retains E1B-
55K late functions to replicate more efficiently in resistant tu-
mor cells but also replicates to almost wild-type virus levels in
primary cells (O’Shea et al., 2004). Moreover, patients treated
with high doses of ONYX-015 in clinical trials have experienced
elevated body temperatures, presumably through inflammatory
effects of virus infusion (Reid et al., 2001). Indeed, these effects
have recently been proposed as a factor that may have signifi-
cantly affected the clinical outcome of ONYX-015 therapy
(Thorne et al., 2005). Our data suggest that a clinical strategy
that does not advocate the use of pharmacological agents to
suppress fever would favor the tumor-selective replication of
ONYX-015. Finally, this study indicates that induction of a heat
shock response by pharmacological agents (that could poten-
tially be administered systemically) or local hyperthermia, could
greatly augment and broaden ONYX-015’s clinical utility as a
cancer therapy.
Experimental procedures
Cell culture
Primary cells were obtained from BioWhittaker, cultured as per the manu-
facturer’s recommendations, and rendered quiescent through contact inhi-
bition followed by prolonged (14–18 days) incubation in complete medium.
Tumor cells were cultured in DMEM, except HCT-116 (McCoy’s) and
HCC3153, HCC38, Ovcar-3 and LNCaP, (RPMI-1640), all of which were
supplemented with 10% fetal calf serum. U2OS 100K and control stable cell
clones were established by transfection with pcDNA3-myc-100K or control
vector, respectively, followed by selection in 500 g/ml G418. Benzoquinoid
ansamycins were obtained from Sigma.
Viral infections and quantification
Viruses included E1A, an E1A-deleted adenovirus (dl312), wild-type virus,
WtD, and E1B-55K-deleted dl1520/ONYX-015 (Barker and Berk, 1987). Vi-
ral infections and viral replication/yield assays were carried out as described
previously (Johnson et al., 2002; O’Shea et al., 2004), at multiplicity of infec-
tions (MOI) that had been determined experimentally (Supplemental Data).
Western blotting and protein translation assays
Cell lysates and immunoblotting were carried out as described previously
(O’Shea et al., 2004). For primary antibodies, see the Supplemental Data.71
A R T I C L EHost protein shutoff assays were performed by analyzing normalized pro-
tein lysates from 35S-methionine-labeled cells (Translabel, NEN) as de-
scribed previously (O’Shea et al., 2004). For methyl7 GTP assays, protein
lysates were prepared in 0.5% NP-40 buffer and precipitated with methyl7
GTP sepharose as described previously (O’Shea et al., 2005).
siRNA
100K siRNA smart pool was obtained from Dharmacon. HCT-116 cells were
transfected with either 100 M 100K silencing siRNA or nonsilencing con-
trol siRNA, using Lipofectamine Plus (Invitrogen). Four hours posttransfec-
tion, media were replaced and cells were infected with adenovirus.
RNA FISH
RNA FISH protocols and fiber/hexon probes were as described previously
(O’Shea et al., 2004). For 100K FISH probe primers, see the Supplemental
Data. Sense and antisense RNA probes were synthesized by in vitro tran-
scription with either T7 or T3 RNA polymerase, respectively, using the Boeh-
ringer DIG RNA labeling kit. DNA was counterstained with either TO-
PRO-3 or DAPI (Molecular Probes), and cells were analyzed on a Zeiss Meta
Laser scanning confocal microscope.
Real-time Q-PCR analysis
RNA was isolated and reverse transcribed, and quantitative PCR analysis
was performed on an ABI Prism 7700, as described previously (O’Shea et
al., 2004). All measurements were performed in triplicate. For normalization,
cDNA equivalent to 12.5 ng input RNA was measured in triplicate for ribo-
somal 18S transcripts (PDAR 18S, ABI). Taqman primers/probes for 100K
and fiber were as described previously (O’Shea et al., 2004).
Hsp expression profiling
RNA was extracted using Trizol (Gibco) and Qiagen RNeasy. Total RNA (20
g) was used to prepare biotin-labeled cRNA according to Affymetrix proto-
cols. RNA/DNA quality/quantity was determined on an Agilent Bioanalyser
2100. cRNA was hybridized to Affymetrix HG U133A chips at the UCSF
Gladstone Genomics Core using standard protocols. Data were analyzed
using Affymetrix MAS 5.1 software and normalized using Robust Multichip
Analysis algorithms (Irizarry et al., 2003). Experiments were performed in
triplicate.
Supplemental data
The Supplemental Data include Experimental Procedures, three figures, and
two tables and can be found with this article online at http://www.cancercell.
org/cgi/content/full/8/1/61/DC1/.
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